AbbVie spent billions of dollars to acquire a potential cancer drug known as Rova-T, but the drug is looking more and more like a bad investment, Business Insider reports.

Details: AbbVie has stopped enrolling new patients in a Phase 3 clinical trial for Rova-T, which an outside monitoring committee had recommended. The drug was intended to treat advanced lung cancer. But in the clinical trial, patients taking Rova-T were dying sooner than patients treated with standard chemotherapy, per BI.